Skip to Main Content

Dr. Terence Friedlander specializes in cancers of the genital and urinary organs, in particular bladder and prostate cancers. His research focuses on understanding the basic biology of these diseases and developing new ways to overcome resistance to treatments.

Friedlander earned his medical degree at New York University School of Medicine and completed a residency in internal medicine at UCSF. He received a Fulbright scholarship in 2006 to study medical ethics, and he completed a fellowship in hematology and oncology at UCSF, when he served as chief fellow. He has also received an American Society of Clinical Oncology Young Investigator Award.

Friedlander is a member of the American Society of Clinical Oncology and American Association for Cancer Research.

  • Board Certifications

    American Board of Internal Medicine, Medical Oncology, 2010

  • Fellowships

    UCSF, Hematology - Oncology, 2010

  • Residencies

    UCSF, Internal Medicine, 2006

  • Internship

    UCSF, Internal Medicine, 2004

  • Education

    NYU Grossman School of Medicine, 2003

  • Languages

    Spanish

    English

With so many new options available for urologic cancers, my hope is that we can harness these treatments to help all our patients.

Where I see patients (2)

    My reviews

    5.0

    Overall Experience
    109 Ratings
    About our process
    Mar 28, 2025
    I appreciate and value the time you dedicate to me to explain and listen to me
    Mar 27, 2025
    UCSF is an amazing hospital
    Mar 25, 2025
    Dr Friedlander is always good about explaining details and providing options.
    Mar 21, 2025
    Dr.Friedlander is very professional, responds quickly to my messages, and is kind, thoughtful, compassionate and always happy to provide background research related to my questions and treatment options.
    Mar 20, 2025
    I feel very fortunate to have such an excellent human being as my doctor
    Mar 15, 2025
    Both Dr. Friedlander and his 'Fellow" were professional, informed, kind and patient.
    Oct 04, 2024
    Dr. Friedlander is extremely attentive.
    Oct 04, 2024
    He's great!
    Sep 28, 2024
    Dr. Friedlander is an exceptional doctor. He genuinely cares and explains everything very well. I feel so privileged to have him as a doctor.
    Sep 12, 2024
    Outstanding experience dealing with the care giver. Couldn't be better
    Aug 31, 2024
    Crucial information and support at this point in our journey
    Aug 22, 2024
    Dr. Friedlander is the very best of the best !
    Aug 03, 2024
    692 days ago I noticed blood in my urine. Tests and biopsies and great advice led us to DrF Through all the care and treatment since then DrF has been informative, empathetic and brilliant. As of Wednesday I am cancer free. He is the best.
    Jul 11, 2024
    Dr. Friedlander is the best!
    May 05, 2024
    Dr.is great communicator
    Apr 21, 2024
    Everybody who works at your facility is amazing and very comforting to talk to
    Apr 20, 2024
    Dr Friedlander is one in 1 million and I am so grateful for him
    Apr 19, 2024
    UCSF staff, nurses, doctors are invariably and unfailingly positive, empathetic, competent and professional. Dr F's excellence stands out as a leader of the exemplary team he leads.
    Apr 06, 2024
    Excellent, highly skilled and compassionate provider. Very fortunate to be working with him!!
    Dec 28, 2023
    DR. FRIEDLANDER IS A KING GOD rockstar!
    Oct 26, 2023
    Dr Friedlander is the best I've encountered!
    Jul 29, 2023
    Clear, empathetic, cutting edge knowledgeable, admits not knowing and finds answers immediately, inspires confidence
    Jun 10, 2023
    Dr. Friedlander is an amazing provider! He's caring, thoughtful and consistent with his level of care! He truly puts the patient as first priority!
    Decorative Caduceus

    Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

    The objective of this study to establish a biorepository of biospecimen and clinical data. There is no primary clinical outcome for this study.

    Recruiting

    Share